ProQR Therapeutics NV (PRQR) Receives Consensus Recommendation of “Buy” from Brokerages

ProQR Therapeutics NV (NASDAQ:PRQR) has received a consensus rating of “Buy” from the nine analysts that are currently covering the firm, MarketBeat.com reports. One analyst has rated the stock with a hold recommendation, six have given a buy recommendation and two have issued a strong buy recommendation on the company. The average twelve-month price objective among analysts that have issued a report on the stock in the last year is $28.00.

A number of equities analysts have recently issued reports on the stock. Cantor Fitzgerald reissued an “overweight” rating on shares of ProQR Therapeutics in a research report on Wednesday, November 14th. Zacks Investment Research raised shares of ProQR Therapeutics from a “hold” rating to a “strong-buy” rating and set a $20.00 price target on the stock in a research report on Wednesday. Chardan Capital reaffirmed a “buy” rating and issued a $21.00 price target on shares of ProQR Therapeutics in a research report on Monday, January 7th. BidaskClub cut shares of ProQR Therapeutics from a “buy” rating to a “hold” rating in a research report on Friday, December 28th. Finally, Royal Bank of Canada began coverage on shares of ProQR Therapeutics in a research report on Wednesday, December 19th. They issued an “outperform” rating on the stock.

PRQR traded up $0.48 during trading on Monday, reaching $15.41. 235,792 shares of the stock traded hands, compared to its average volume of 369,387. The stock has a market capitalization of $631.45 million, a P/E ratio of -7.94 and a beta of 0.81. The company has a current ratio of 11.39, a quick ratio of 11.39 and a debt-to-equity ratio of 0.06. ProQR Therapeutics has a 12 month low of $2.80 and a 12 month high of $24.00.

ProQR Therapeutics (NASDAQ:PRQR) last released its quarterly earnings data on Wednesday, November 7th. The biopharmaceutical company reported ($0.21) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.31) by $0.10. As a group, research analysts predict that ProQR Therapeutics will post -1.24 EPS for the current fiscal year.

Hedge funds and other institutional investors have recently made changes to their positions in the stock. Ardsley Advisory Partners bought a new position in ProQR Therapeutics in the 2nd quarter valued at about $365,000. Nexthera Capital LP purchased a new stake in ProQR Therapeutics in the 3rd quarter valued at about $1,023,000. Millennium Management LLC purchased a new stake in ProQR Therapeutics in the 2nd quarter valued at about $1,426,000. Monashee Investment Management LLC purchased a new stake in ProQR Therapeutics in the 3rd quarter valued at about $2,129,000. Finally, Federated Investors Inc. PA purchased a new stake in ProQR Therapeutics in the 3rd quarter valued at about $5,058,000. 50.13% of the stock is currently owned by institutional investors and hedge funds.

ProQR Therapeutics Company Profile

ProQR Therapeutics N.V., a biopharmaceutical company, engages in the discovery and development of RNA-based therapeutics for the treatment of genetic disorders. Its lead product candidates include eluforsen, a RNA-based oligonucleotide used for the treatment of cystic fibrosis; QR-110, an oligonucleotide that is designed to treat Leber's congenital amaurosis; QR-313, a dermatology candidate for the treatment of epidermolysis bullosa; and QR-421a and QR-411 to treat type 2A Usher syndrome.

See Also: Discount Rate

Analyst Recommendations for ProQR Therapeutics (NASDAQ:PRQR)

Receive News & Ratings for ProQR Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ProQR Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit